Ganten M-K, Weber M A, Ganten T M
Abteilung für Radiologie, Deutsches Krebsforschungszentrum, Heidelberg, Deutschland.
Radiologe. 2008 Sep;48(9):820-31. doi: 10.1007/s00117-008-1739-1.
Diseases caused by cancer have become more common due to an increase in life-expectation, but the probability of reaching an old age with or without a tumor disease is still increasing. According to the statistics of the German Cancer register, at present more than half of cancer patients survive for at least 5 years after cancer has been diagnosed. Many tumors can be cured using innovative neoadjuvant and adjuvant therapy regimes, but the options for palliative therapy have also been improved. This leads to an increasing importance of the evaluation of the tumor response using imaging techniques. Classically, tumor response is measured by imaging using the RECIST (response evaluation criteria in solid tumors) criteria, which define the changes in size of the tumor during therapy. However, there is increasingly more evidence that RECIST as the only measure of tumor response, does not document tumor response for all tumor entities and especially not for many medications known as targeted therapy. This article gives a review of the principles and mode of effect of various therapy regimes as well as the clinical demands on imaging techniques.
由于预期寿命的增加，癌症引发的疾病变得更加常见，但无论是否患有肿瘤疾病，活到老年的概率仍在上升。根据德国癌症登记处的统计数据，目前超过一半的癌症患者在确诊癌症后至少存活5年。许多肿瘤可以通过创新的新辅助和辅助治疗方案治愈，姑息治疗的选择也有所改善。这使得使用成像技术评估肿瘤反应的重要性日益增加。传统上，肿瘤反应通过使用实体瘤疗效评价标准（RECIST）进行成像测量，该标准定义了治疗期间肿瘤大小的变化。然而，越来越多的证据表明，作为肿瘤反应唯一衡量标准的RECIST，并未记录所有肿瘤实体的肿瘤反应，尤其是许多被称为靶向治疗的药物的肿瘤反应。本文综述了各种治疗方案的原理和作用方式以及对成像技术的临床要求。
